Market Place
Sourcing Support
All News #Library
Rare Diseases
Denali’s Hunter Syndrome Drug Gains Focus After REGENXBIO Setback
16 Mar 2026 //
BIOSPACE
Regenxbio Gene Therapy Passes Interim Test As Pivotal Data Loom
12 Mar 2026 //
FIERCE BIOTECH
Regenxbio Unveils Positive Interim Data from RGX-202 Phase I/II
11 Mar 2026 //
PR NEWSWIRE
REGENXBIO Announces Regulatory Update On RGX-121 BLA For MPS II
10 Feb 2026 //
PR NEWSWIRE BIO
Sarepta Challenges Prompt Search For Advancements In DMD Therapy
09 Feb 2026 //
BIOSPACE
FDA Rejects Regenxbio`s Hunter Syndrome Gene Therapy
09 Feb 2026 //
FIERCE BIOTECH
FDA Places Clinical Hold on Regenxbio`s Rare Disease Program
28 Jan 2026 //
REUTERS
FDA Raises Bar in Rare Diseases as RegenxBio Nears Pivot
22 Jan 2026 //
STATNEWS
REGENXBIO Completes Pivotal Enrollment, Duchenne Gene Therapy
30 Oct 2025 //
PR NEWSWIRE
FDA Accepts License Application for MPS II Treatment
14 May 2025 //
PR NEWSWIRE
Sanifit touts positive PhIIb data; REGENXBIO licenses Clearside Biomedical tech
31 Oct 2019 //
ENDPTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.